Literature DB >> 11581526

Long-term Medical Treatment for Parkinson's Disease.

John M. Bertoni1, Jose-Luis Prendes, Pamela Sprenkle.   

Abstract

The authors of this paper view Parkinson's disease (PD) as a clinically defined progressive syndrome of resting limb tremor, bradykinesia, muscle rigidity, and a shuffling unsteady gait that responds well to dopaminergic medications. Parkinson's disease is a not a single entity, but rather a syndrome with diverse causes, with both genetic and environmental risk factors. The clinician's concern is to rule out other entities, especially those having another specific treatment, and to give PD patients the best short- and long-term benefit, with the least possible unwanted side effects.

Entities:  

Year:  2001        PMID: 11581526     DOI: 10.1007/s11940-001-0012-y

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.598


  28 in total

1.  Rehabilitation for patients with Parkinson's disease.

Authors:  A J Thompson; E D Playford
Journal:  Lancet       Date:  2001-02-10       Impact factor: 79.321

Review 2.  Surgery for Parkinson disease: A critical evaluation of the state of the art.

Authors:  A E Lang
Journal:  Arch Neurol       Date:  2000-08

Review 3.  Thalamic, pallidal, or subthalamic surgery for Parkinson's disease?

Authors:  P Krack; M Poepping; D Weinert; B Schrader; G Deuschl
Journal:  J Neurol       Date:  2000-04       Impact factor: 4.849

4.  Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease.

Authors:  J H Carter; J G Nutt; W R Woodward; L F Hatcher; T L Trotman
Journal:  Neurology       Date:  1989-04       Impact factor: 9.910

5.  A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.

Authors:  A Lieberman; C W Olanow; K Sethi; P Swanson; C H Waters; S Fahn; H Hurtig; M Yahr
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

Review 6.  Parkinson's disease therapy: tailoring choices for early and late disease, young and old patients.

Authors:  J Jankovic
Journal:  Clin Neuropharmacol       Date:  2000 Sep-Oct       Impact factor: 1.592

7.  Amantadine for Parkinson's disease.

Authors:  D C Mann; L A Pearce; L D Waterbury
Journal:  Neurology       Date:  1971-09       Impact factor: 9.910

8.  Amantadine in the treatment of Parkinson's disease.

Authors:  R S Schwab; A C England; D C Poskanzer; R R Young
Journal:  JAMA       Date:  1969-05-19       Impact factor: 56.272

9.  Movement disorders in people with Parkinson disease: a model for physical therapy.

Authors:  M E Morris
Journal:  Phys Ther       Date:  2000-06

10.  Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.

Authors:  M Merello; A J Lees; R Webster; M Bovingdon; A Gordin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-02       Impact factor: 10.154

View more
  2 in total

1.  Face-referenced measurement of perioral stiffness and speech kinematics in Parkinson's disease.

Authors:  Shin Ying Chu; Steven M Barlow; Jaehoon Lee
Journal:  J Speech Lang Hear Res       Date:  2015-04       Impact factor: 2.297

2.  Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.

Authors:  Tohru Kitada; Julianna J Tomlinson; Hei Sio Ao; David A Grimes; Michael G Schlossmacher
Journal:  Curr Treat Options Neurol       Date:  2012-06       Impact factor: 3.598

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.